An Observational Study on Long Term Safety and Efficacy of Ivabradine in Patients with Chronic Heart Failure

Dr. Nikhilesh Andhi*, P. Dhakshayani, K. Supriya, D. Aravind, M. Laharika

*Assistant Professor, Department of Clinical Pharmacy Practice, Samskruti College of Pharmacy, Kondapur, Ghatkesar, Medchal District, Telangana, India.

*Corresponding author’s E-mail: 2016marsn@gmail.com

Received: 11-02-2022; Revised: 18-04-2022; Accepted: 28-04-2022; Published on: 15-05-2022.

ABSTRACT

The chief objective of the study is to find out the safety and efficacy of ivabradine in patients with chronic heart failure. A prospective observational study has been guided in the cardiology department of tertiary care hospital. The data is collected from the out-patient and in-patient department after considering inclusion and exclusion principles for 6 months and a total of 220 patients were analyzed with data collection form by interviewing to the patients about the Socio-demographic questionnaire, MLHFQ (Minnesota Living and Heart Failure Questionnaire) for the evaluation of safety and efficacy of ivabradine and quality of life after Heart Failure. Statistical tools like the Chi-square test were applied to the data by using SPSS software. A total amount of 220 Heart Failure patients, males 148 (67.3%) patients were predominant over female patients of 72 (32.7%). The majority of the Heart Failure patients were under the peer group of >60 years (100%), symptoms were more in males (46%), past medical history i.e. Hypertension and Diabetes mellitus were more in number (128), Coronary Artery Disease (Anterior Wall Myocardial Infarction) (32), Non ST Elevated Myocardial Infarction (8). Most of the patients were treated with the dose of ivabradine i.e. 5mg rather than 2.5mg or 7.5mg. Among 5mg (90.9%), 2.5mg (5.5%) and 7.5mg (3.6%). The ivabradine is used for decreasing Heart Rate among all age groups i.e. >35 years are having more Heart Rate before ivabradine intake. After ivabradine intake, the normal Heart Rate is seen in age groups of 35-40 years. Adverse effects of ivabradine are bradycardia (10%), Hypertension (8.9%), atrial fibrillation (8.3%), and luminous phenomenon (2.8%). Heart Failure is mostly seen in males and elderly people. The present study shows the safety and efficacy with respect to ivabradine in patient with congestive Heart Failure. After intake of ivabradine, the Heart Rate was bought to normal which shows the efficacy of the drug and the adverse effects are bradycardia, hypertension, atrial fibrillation, luminous phenomenon. But these adverse reactions were not seen in the sample size. This shows the safety of the drug.

Keywords: Heart failure, Ivabradine, Heart Rate, Hypertension, Bradycardia, Atrial fibrillation, luminous phenomenon.

INTRODUCTION

The ‘pure’ heart rate lowering antianginal drug which has been introduced recently as an alternative to β-blocker is ‘IVABRADINE’. Ivabradine (eye-VAB-a-deen) is the only authorized drug come under the category of HCN channel. If current was first discovered in the 1970s in animal studies, which is found to be primarily mediated in humans by abundant SA node HCNs. This drug is also used by children who’s suffering from heart failure as a consequence of an enlarged heart viz. dilated cardiomyopathy. Dosage in adults: Initial dose: 5mg BD, If heart rate> 70bpm the maximum dosage is 7.5mg. Pediatric Tablet: 5mg divided into equal halves to provide a dose of 2.5mg. The maximum dose for age 6 months to < 1 year the dose shouldn’t increase equal to 0.2mg/kg BD, Maximum for age ≥ 1 year supposed to be 0.3mg /kg BD, and the dose shall not be increased up to 7.5mg BD. The patient who develops bradycardia. The recommended initial dose considers reducing the dose to 0.02mg/kg BID.

Mechanism of Action

The heart rate is persistent by the rate & thus the amount is explained by the rate of spontaneous diastolic depolarization in the SA node. The spontaneous diastolic depolarization is determined by a mixed Na⁺ - K⁺ current across Iak channels. It is directly and particularly restrained by ivabradine, which leads to reduced diastolic depolarization rate and declining of the heart rate. Ivabradine enters and blocks the f- channels from the protoplasm side of the plasma membrane and it does mostly when the channel is in the open state. Therefore, it prevents the rate of cardiac pacemaker movement of the heart. Ivabradine specified modes of action is to limit its usage to patients with sinus rhythm and prohibits in patients who are suffering from AF or AFL.

Therapeutic use of Ivabradine is utilized in heart failure to improve symptoms in patients who are having sinus rhythm with a heart rate of above > 70/min and are optimized for heart failure treatment. Pharmacokinetic parameters include absorption. Taking ivabradine during meals minimizes intra-individual variableness in absorption time. Distribution The volume of distribution...
(≈ 100L), under fasting conditions, it reaches peak plasma concentrations i.e. approximately 1 hour. Metabolism is metabolized by both liver and gut by oxidation through cytochrome P450 3A4 (CYP3A4). The active metabolite is N-desmethylated derivative. Ivabradine must not be co-prescribed with strong or moderate CYP3A4 inhibitors such as diltiazem and verapamil. Elimination of ivabradine’s main half-life is approximately 2 hours i.e. 70–75% of AUC and its effective half-life is around 11 hours. Clearance is about 400 ml per minute. About 4% is excreted and unchanged via urine. Pharmacodynamics effects include ivabradine impetus a dose-dependent reduction in heart rate. At the recommended dosage, the heart rate declining is grossly 10 bpm while asleep or exercising. In clinical practice and particularly in subjects with co-morbidities, ivabradine does not influence intra cardiac conduction, contractility, or ventricular repolarization nor it does not affect the central aortic pressure or LV after load. Ivabradine does not exert negative inotropic effects. It increases the uncorrected QT interval with heart rate slowing but it does not prolong the QT interval. Side effects and adverse effects include Headache: During the first month of treatment. Blurred vision, ventricular extra systole. The most basic adverse effects of ivabradine consist of bradycardia, atrial fibrillation, high blood pressure, and phosphenes. Luminous visual phenomenon and bradycardia two are dose-dependent and interconnected to the pharmacological effect. The If channels are inhibited by the ivabradine which is present in the eyeball. Because of the current is inhibited by visual phenomena. It usually occurs mild-moderate. Generally, it occurs within 2 months of treatment initiation. The ivabradine medication is used to decrease the heart rate. But if the drug is used continuously used even later the heart rate is brought to normal. Then the heart rate is decreased.

Contraindications include Decompensated Heart Failure, BP lower than 90/50, Conduction abnormalities i.e. sick sinus syndrome, sinoatrial block, or third-degree AV block, unless a pacemaker determines the heart rate, Severe liver impairment, Patients taking cytochrome P450 3A4 (CYP3A4), Resting heart rate not exceeding 60 bpm before therapy initiation. Ivabradine causes drug-drug interaction with CYP450 inhibitors. It may cause fetal toxicity when it is inclined to pregnant lady. Effective contraception in women is recommended while using ivabradine. BRAND NAMES: IVABRAD, BRADIA, IVABEAT 5mg, 7.5 mg tab.

MATERIALS AND METHODS

A prospective observational study conducted in cardiology department in a tertiary care hospital for duration of 6 months.

The data was gathered from the in-patient and out-patient department by interviewing the patients and reviewing their prescriptions. The data collection format was verified and authenticated by the hospital preceptors for the study. Study involved 220 patients

Subjects who were diagnosed with heart failure with treatment of ivabradine. Patients with pregnancy, lactating patients, renal patients and hepatic patients are excluded from the study.

Written informed consent was taken from patient or care provider to collect data. The data form includes socio-demographic information like age, gender, weight, marital status, educational status, Past Medical History, social history, family history, and MLHFQ questionnaire was attached to it.

Statistical Analysis: Descriptive statistics was done by using SPSS software to determine mean and standard deviation of collected data. The statistical tool Chi square test was performed to determine P-value between the different variable with data collected (gender vs after heart rate, dosage vs after heart rate, past medical history hypertension vs before heart rate, past medical history vs before heart rate, before heart rate vs after heart rate). The P-value is used in determining the statistical significance within statistical hypothesis for drug related problem in heart failure patients to baseline visit. The P-value was set at <0.05 and confidence interval was 95%

RESULTS

In present study around 220 cases were included as per our criteria. Table -1 indicates socio demographic details of the patient with the treatment of ivabradine. Male patients (67.3%) seems to be predominant than female patients (32.7%). Fig 1 shows the gender wise distribution of the study population. Fig 2 represents the age wise distribution of patients with respect to gender as shown in the table 1 here it is represented that 60’yrs were highest (100%) and < 35 and 35- 40yrs were least (12%) which is shown in the figure 2. In Fig 3 represents the symptoms most of the patients have experienced symptoms of chest pain and irregular heart beat (46%) and less number of patients experienced fatigue (19%) which is represented in the fig 3. Fig 4 as shown in the table 1 represents he past medical history of the patients here most of the patients have past medical history of Hypertension and Diabetes Mellitus which is represented in the fig 4. Fig 5 as shown in the table 1 represents dosage therapy and explains the average dose of patients who have taken 2.5mg were (12), 5mg were (200) and 7.5mg were (8). But maximum dosage of ivabradine is 5mg is taken by the most of the patients. Fig 6 as shown in the table 1 explains about the before and after heart rates of ivabradine in patients with different age groups i.e. <35yrs, 35- 40yrs, 40-50yrs, 50- 60yrs and >60yrs were observed. Most common adverse effects were observed in patients i.e. bradycardia (10%), hypertension (8.9%), atrial fibrillation (8.3%) and luminous phenomenon (2.8%) are indicated in Fig 7. Here in fig 7 we can observe that most common adverse effect which is seen in the patients who are taking ivabradine is...
bradycardia. Fig 8 represents deviation in heart rate in order to prove the efficacy of ivabradine on an average of 55 patients. Here in fig 8 the dark blue colour indicates heart rate before intake of ivabradine and red colour indicates heart rate after intake of ivabradine, thus through the figure 8 we can clearly see the deviation in graph which is indicating the decrease in the heart rate providing the evidence of its efficacy. Chi square test was performed between variables like gender vs after heart rate (0.001), dosage vs after heart rate (0.001), past medical history hypertension vs before heart rate (0.074), past medical history vs before heart rate (0.004), before heart rate vs after heart rate (0.001), age vs cad (0.055) and P-value was clinically significant (<0.005).

Table 1: Mean, SD, P-value

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>N</th>
<th>Mean</th>
<th>Standard Deviation</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>220</td>
<td>59.04</td>
<td>11.940</td>
<td>0.0001</td>
</tr>
<tr>
<td>Past Medical History I HTN</td>
<td>220</td>
<td>.62</td>
<td>.487</td>
<td>0.0001</td>
</tr>
<tr>
<td>Past Medical History II DM</td>
<td>220</td>
<td>.56</td>
<td>.487</td>
<td>0.0001</td>
</tr>
<tr>
<td>Past Medical History III CAD</td>
<td>220</td>
<td>.20</td>
<td>.401</td>
<td>0.0001</td>
</tr>
<tr>
<td>Ivabradine Dose</td>
<td>220</td>
<td>5.05</td>
<td>.402</td>
<td>0.0001</td>
</tr>
<tr>
<td>Before HR</td>
<td>220</td>
<td>103.89</td>
<td>11.294</td>
<td>0.0001</td>
</tr>
<tr>
<td>After HR</td>
<td>220</td>
<td>79.35</td>
<td>9.699</td>
<td>0.0001</td>
</tr>
</tbody>
</table>

Figure 1: Gender Wise Distribution

Figure 2: Age Wise Distribution Graph with Respect to Gender

Figure 3: Percentage of Symptoms
Figure 4: Past Medical History of Patients

Figure 5: Dosage Therapy

Figure 6: Before and After Heart Rates of Ivabradine Based on their Age Groups
DISCUSSION

A prospective observational study, “AN OBSERVATIONAL STUDY ON LONG TERM SAFETY & EFFICACY OF IVABRADINE IN PATIENTS WITH CHEART RATEONIC HEART FAILURE” was conducted in secondary care hospital in outpatient and inpatient department. The data is collected for 220 patients using data collection forms.

According to our study among 220 patients, most of the heart failure patients were subordinate under the age group of >60 years (100%); males were (67.3%) and females were (32.7%). Similar nature of findings were reported by K K Adile, A Kapoor, S K Jain, A Gupta. In the current study, past medical history has more in number (128), viz. Hypertension and Diabetes Mellitus (128), Coronary Artery Disease (Anterior Wall Myocardial Infraction) (32), Non St Elevated Myocardial Infraction (8). Past medical history has reported by 60% of people. A study by Michel Komajda, Luigi Tavazzi were showed nearly 80% of people were presented with similar PMH.

Chi square test was performed in our study showed that p-value was clinically significant, for all socio demographic details and therapy. In the present study among 220 patients 46% were with chest pain and irregular heartbeat, 35% were with wheezing and fainting and fatigue were 19% which is similar Lynn Elzir, Eileen O Meara, 24, 25. Ivabradine maintenance dose not exceed 7.5mg twice daily. So in this study 2.5mg dose were (5.5%), 5mg dose were treated in (90.9%) and 7.5mg dose were only (3.6%). Similarly findings reported by Yasar Sattar, Elham Neisani Samani and Nirav B Patel. According to this study the heart rate was high in age group <35 years rather than other groups. Before intake of ivabradine which is similarly see in study by Ajit Mullasari. The drug ivabradine has some adverse reactions viz. bradycardia (10.9%), hypertension (8.9%), atrial fibrillation (8.3%), luminous phenomenon.
(2.6%). A study was presented with similar symptoms. It was observed from our study that, ivabradine will help in lowering the heart rate and it also have some side effects like bradycardia, atrial fibrillation, hypertension, luminous phenomenon. No adverse reactions were reported in our study.

CONCLUSION

Heart Failure is mostly seen in males, elderly people viz. under >60 years of age group. Present study shows the safety and efficacy of ivabradine. In recent study ivabradine is preferred for heart failure. Among Ca^2+ channel blockers ivabradine is vital for clinical management in decreasing the heart rate in heart failure also it is accompanied by some sort of the side effects, but dose adjustments are done to avoid these effects. The research encourages that proper involvement of clinical pharmacist and their duty is to serve to identify and avoid to drug related problems as implicated. By doing so, mortality and further complication must be prevented. During the study it proves that the patients were treated with ivabradine. The drug interactions were moderately found which can overcome by alterations of frequencies. Ivabradine has shown greater effects in decreasing the heart rate which demonstrates the effectiveness of the drug & no adverse reactions were observed in our study that implies the safety of the drug.

REFERENCES


Source of Support: The author(s) received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

For any question relates to this article, please reach us at: globalresearchonline@rediffmail.com

New manuscripts for publication can be submitted at: submit@globalresearchonline.net and submit_ijpsrr@rediffmail.com